Phase II Single Arm Study of Everolimus and Pasireotide (SOM230) in Patients with Advanced or Metastatic Hepatocellular Carcinoma (HCC).

Trial Profile

Phase II Single Arm Study of Everolimus and Pasireotide (SOM230) in Patients with Advanced or Metastatic Hepatocellular Carcinoma (HCC).

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Apr 2016

At a glance

  • Drugs Everolimus (Primary) ; Pasireotide (Primary)
  • Indications Liver cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 23 Mar 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 28 Mar 2014 Planned End Date changed from 1 Jun 2013 to 1 Jun 2015 as reported by ClinicalTrials.gov.
    • 28 Mar 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top